Grace Century’s stem cell bio-banking portfolio project Provia Laboratories has once again achieved record enrolments, with November company sales numbers increasing by a huge 66 per cent compared to the same period last year. Provia has now exceeded their total 2014 enrolments by over 40 per cent in 2015 year-to-date, with a full month of 2015 remaining.
Ras Al Khaimah, United Arab Emirates – Grace Century’s biobanking project, Provia Laboratories LLC has announced another record enrolment month for their Store-a-Tooth™ dental stem cell biobanking service, as well as record projected year-end numbers.
Provia reported a +66 per cent increase in November 2015 compared to the same month in 2014. Furthermore, with the full month of December left to go, the firm already stands at +42 per cent ahead in enrolments for 2015 compared to the entire 2014 calendar year.
Increases are attributed to continued international expansion, improved performance of its dental channel strategy, and continued investment in consumer awareness. In addition, the recent launch of Provia’s new cGMP 10,000sqft-laboratory facility has dramatically opened the opportunities to peripheral revenue streams in commercial stem cell services.
Store-a-Tooth technology enables the safe storing of dental stem cells harvested from baby teeth, which have the potential to be used in future personalised and regenerative medicine treatments for illnesses such as Type 1 diabetes, cancer and Parkinson’s disease. In the last 18 months, interest in the possibilities around stem cells has grown significantly within the medical and scientific communities, as more and more research breakthroughs and real-life success stories are being reported.
Grace Century’s CEO, Scott Wolf, comments, “These are exceptional numbers for any business. Provia’s progress in 2015 serves as a launch pad for when both Europe and Russian territories come on line in the first quarter of 2016.”
Howard Greenman, CEO of Provia, says, “We are seeing the results of staying committed to our mission, which is to treat our client’s cells like they belong to our own children; to make technologies supporting cellular medicine broadly accessible and deliver quality products and services that accelerate the development of cellular therapies. Families are valuing our commitment to quality, dentists are entrusting us with their interested patients, and commercial partners are leveraging our experience with these technologies to advance their pursuit of cellular therapy.”
